📊 AARD Key Takeaways
Is Aardvark Therapeutics, Inc. (AARD) a Good Investment?
Aardvark Therapeutics is a pre-revenue pharmaceutical company with zero cash generation, operating losses of $22.5M, and sharply deteriorating net losses (down 179.7% YoY). While the balance sheet is strong with $62.4M cash and zero debt, the accelerating burn rate and absence of revenue indicate fundamental business dysfunction requiring urgent turnaround or additional capital infusion.
Aardvark Therapeutics is a pre-revenue pharmaceutical company with no current commercial income, deeply negative operating and net results, and materially negative free cash flow, indicating the business is still in a heavy development stage rather than demonstrating operating viability. Its balance sheet is a clear offset, with substantial cash, very low liabilities, and no meaningful debt, but the current fundamentals depend on cash runway rather than proven revenue generation or earnings quality.
Aardvark Therapeutics, Inc. Key Strengths (AARD)
- Strong cash position of $62.4M provides 3+ year runway at current burn rate
- Excellent liquidity ratios (8.06x current/quick ratio) enable operational flexibility
- Zero debt and clean balance sheet with $87M stockholders equity reduce financial distress risk
- Strong liquidity with $39.28M in cash and a 12.03x current ratio
- Low balance-sheet risk due to minimal liabilities and essentially no long-term debt
- Large equity base of $122.38M provides financial flexibility relative to current obligations
AARD Stock Risks: Aardvark Therapeutics, Inc. Investment Risks
- Complete revenue collapse ($0 YoY) indicates failed commercialization or abandoned pipeline
- Net losses deteriorating severely at 179.7% YoY rate suggesting accelerating cash burn
- Operating cash outflow of $18.9M annually unsustainable long-term; cash runway finite despite adequate balance sheet
- No insider activity in 90 days suggests either restricted trading or lack of management confidence
- No revenue base, making profitability and growth quality unproven
- High operating and free cash flow losses suggest continued cash burn and likely future financing needs
- Negative ROE and ROA indicate weak capital efficiency and asset productivity
Key Metrics to Watch
- Quarterly cash burn rate and months of cash remaining
- Path to revenue generation or clinical milestone achievements
- Operating loss trend - stabilization or further deterioration
- Capital raise activity and dilution impact on equity
- Quarterly operating cash burn relative to cash balance
- Any transition from zero revenue to recurring collaboration, licensing, or product revenue
Aardvark Therapeutics, Inc. (AARD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.06x current ratio provides a solid financial cushion.
AARD Profit Margin, ROE & Profitability Analysis
AARD vs Healthcare Sector: How Aardvark Therapeutics, Inc. Compares
How Aardvark Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aardvark Therapeutics, Inc. Stock Overvalued? AARD Valuation Analysis 2026
Based on fundamental analysis, Aardvark Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aardvark Therapeutics, Inc. Balance Sheet: AARD Debt, Cash & Liquidity
AARD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aardvark Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.15 indicates the company is currently unprofitable.
AARD Revenue Growth, EPS Growth & YoY Performance
AARD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$9.3M | $-0.71 |
| Q3 2025 | N/A | -$4.2M | $-0.75 |
| Q2 2025 | N/A | -$5.4M | $-0.66 |
| Q1 2025 | N/A | -$2.2M | $-0.55 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aardvark Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
AARD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aardvark Therapeutics, Inc. (CIK: 0001774857)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AARD
What is the AI rating for AARD?
Aardvark Therapeutics, Inc. (AARD) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AARD's key strengths?
Claude: Strong cash position of $62.4M provides 3+ year runway at current burn rate. Excellent liquidity ratios (8.06x current/quick ratio) enable operational flexibility. ChatGPT: Strong liquidity with $39.28M in cash and a 12.03x current ratio. Low balance-sheet risk due to minimal liabilities and essentially no long-term debt.
What are the risks of investing in AARD?
Claude: Complete revenue collapse ($0 YoY) indicates failed commercialization or abandoned pipeline. Net losses deteriorating severely at 179.7% YoY rate suggesting accelerating cash burn. ChatGPT: No revenue base, making profitability and growth quality unproven. High operating and free cash flow losses suggest continued cash burn and likely future financing needs.
What is AARD's revenue and growth?
Aardvark Therapeutics, Inc. reported revenue of $0.0.
Does AARD pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
Where can I find AARD SEC filings?
Official SEC filings for Aardvark Therapeutics, Inc. (CIK: 0001774857) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AARD's EPS?
Aardvark Therapeutics, Inc. has a diluted EPS of $-0.99.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AARD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Aardvark Therapeutics, Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AARD stock overvalued or undervalued?
Valuation metrics for AARD: ROE of -24.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AARD's AI grade for 2026?
Our dual AI analysis gives Aardvark Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AARD's free cash flow?
Aardvark Therapeutics, Inc.'s operating cash flow is $-18.9M, with capital expenditures of $95.0K.
How does AARD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -24.8% (avg: 15%), current ratio 8.06 (avg: 2).